By RJ Vogt ( January 17, 2018, 11:07 PM EST) -- The U.S. Patent Trial and Appeal Board ruled Wednesday that a patent for Johnson & Johnson's Zytiga prostate cancer drug described an obvious process, invalidating the last remaining patent blocking Argentum Pharmaceuticals LLC from making a generic version of a product that reaped $2.26 billion in sales in 2016....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.